MicroRNA-targeted therapy is a molecular oncology mechanism in which an anti-miRNA agent inhibits an overexpressed microRNA implicated in malignant cell proliferation, providing a targeted treatment rationale distinct from cytotoxic chemotherapy. Early-phase clinical trial methodology evaluates such an agent's safety (adverse event profile) and preliminary efficacy (disease response and stabilization) in a defined patient population, with biomarker overexpression used to identify additional disease populations that may share the same therapeutic target. This belongs to translational hematology-oncology and clinical pharmacology, linking molecular biomarker science to early-phase (Phase I) clinical trial design.
MicroRNA-targeted therapy is a molecular oncology mechanism in which an anti-miRNA agent inhibits an overexpressed microRNA implicated in malignant cell proliferation, providing a targeted treatment …